Literature DB >> 24491979

Simplifying the complexity of resistance heterogeneity in metastasis.

Orit Lavi1, James M Greene2, Doron Levy2, Michael M Gottesman3.   

Abstract

The main goal of treatment regimens for metastasis is to control growth rates, not eradicate all cancer cells. Mathematical models offer methodologies that incorporate high-throughput data with dynamic effects on net growth. The ideal approach would simplify, but not over-simplify, a complex problem into meaningful and manageable estimators that predict the response of a patient to specific treatments. We explore here three fundamental approaches with different assumptions concerning resistance mechanisms in which the cells are categorized into either discrete compartments or described by a continuous range of resistance levels. We argue in favor of modeling resistance as a continuum, and demonstrate how integrating cellular growth rates, density-dependent versus exponential growth, and intratumoral heterogeneity improves predictions concerning the resistance heterogeneity of metastases. Published by Elsevier Ltd.

Entities:  

Keywords:  cell density; clinical application; mathematical model; metastasis; resistance level; tumor heterogeneity

Mesh:

Year:  2014        PMID: 24491979      PMCID: PMC3962236          DOI: 10.1016/j.molmed.2013.12.005

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  24 in total

1.  Cancer. Cancer cell phenotypes, in fifty shades of grey.

Authors:  Andriy Marusyk; Kornelia Polyak
Journal:  Science       Date:  2013-02-01       Impact factor: 47.728

Review 2.  The dynamics of drug resistance: a mathematical perspective.

Authors:  Orit Lavi; Michael M Gottesman; Doron Levy
Journal:  Drug Resist Updat       Date:  2012-03-03       Impact factor: 18.500

3.  Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.

Authors:  Wilfred D Stein; Julia Wilkerson; Sindy T Kim; Xin Huang; Robert J Motzer; Antonio Tito Fojo; Susan E Bates
Journal:  Clin Cancer Res       Date:  2012-02-17       Impact factor: 12.531

4.  Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer.

Authors:  Antonija Kreso; Catherine A O'Brien; Peter van Galen; Olga I Gan; Faiyaz Notta; Andrew M K Brown; Karen Ng; Jing Ma; Erno Wienholds; Cyrille Dunant; Aaron Pollett; Steven Gallinger; John McPherson; Charles G Mullighan; Darryl Shibata; John E Dick
Journal:  Science       Date:  2012-12-13       Impact factor: 47.728

5.  Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.

Authors:  Wilfred D Stein; James L Gulley; Jeff Schlom; Ravi A Madan; William Dahut; William D Figg; Yang-Min Ning; Phil M Arlen; Doug Price; Susan E Bates; Tito Fojo
Journal:  Clin Cancer Res       Date:  2010-11-24       Impact factor: 12.531

6.  Somatic LMCD1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma.

Authors:  C-Y Chang; S-C Lin; W-H Su; C-M Ho; Y-S Jou
Journal:  Oncogene       Date:  2011-09-26       Impact factor: 9.867

Review 7.  Cellular heterogeneity and molecular evolution in cancer.

Authors:  Vanessa Almendro; Andriy Marusyk; Kornelia Polyak
Journal:  Annu Rev Pathol       Date:  2012-10-22       Impact factor: 23.472

8.  Does tumor growth follow a "universal law"?

Authors:  Caterina Guiot; Piero Giorgio Degiorgis; Pier Paolo Delsanto; Pietro Gabriele; Thomas S Deisboeck
Journal:  J Theor Biol       Date:  2003-11-21       Impact factor: 2.691

Review 9.  Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives.

Authors:  Nicholas A Saunders; Fiona Simpson; Erik W Thompson; Michelle M Hill; Liliana Endo-Munoz; Graham Leggatt; Rodney F Minchin; Alexander Guminski
Journal:  EMBO Mol Med       Date:  2012-06-25       Impact factor: 12.137

10.  Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma.

Authors:  Krastan B Blagoev; Julia Wilkerson; Wilfred D Stein; Robert J Motzer; Susan E Bates; A Tito Fojo
Journal:  Cell Rep       Date:  2013-02-07       Impact factor: 9.423

View more
  3 in total

1.  Redundancy: a critical obstacle to improving cancer therapy.

Authors:  Orit Lavi
Journal:  Cancer Res       Date:  2015-01-09       Impact factor: 12.701

2.  Interplay of Darwinian Selection, Lamarckian Induction and Microvesicle Transfer on Drug Resistance in Cancer.

Authors:  Arturo Álvarez-Arenas; Ana Podolski-Renic; Juan Belmonte-Beitia; Milica Pesic; Gabriel F Calvo
Journal:  Sci Rep       Date:  2019-06-27       Impact factor: 4.379

3.  Niche inheritance: a cooperative pathway to enhance cancer cell fitness through ecosystem engineering.

Authors:  Kimberline R Yang; Steven M Mooney; Jelani C Zarif; Donald S Coffey; Russell S Taichman; Kenneth J Pienta
Journal:  J Cell Biochem       Date:  2014-09       Impact factor: 4.429

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.